Medium Risk

Indoco Remedies Limited

Manufacturing and sales of Pharmaceuticals

CIN: L85190MH1947PLC005913 FY: - Revenue: ₹1,494.8 Cr
5.3
ESG Risk
Score /10
Compliance RiskEpr ExposureGhg Intensity

Risk Breakdown

GHG Intensity
5.0
Water Intensity
5.0
Waste Intensity
1.0
EPR Exposure
6.5
Compliance Risk
10.0
HR Risk
3.0
Governance Risk
5.0

Financial Exposure

Est. Compliance Cost₹2–9 crore
EPR ApplicableUnknown
Scope 1 Emissions— tCO2e
Scope 2 Emissions— tCO2e
Water Withdrawal— m³
Waste Generated304.4 T

Governance

Anti-Corruption PolicyYes
Conflict of Interest PolicyUnknown
BRSR AssuranceNone
Assurance Provider

Double Materiality

Financial Materiality5.3
Impact Materiality4.6
QuadrantFinancially Material

Supply Chain

MSME Sourcing0.3%
Lifecycle AssessmentNo
Product ReclaimYes

Material Risks

e-waste

ESG Targets & Commitments

TopicTarget / MetricStatus
Human Rights in Supply Chain HR clauses in all contracts Commitment

AI Risk Summary

**Financial Risk Summary: Indoco Remedies Limited** Indoco faces critical compliance exposure with a maximum 10.0/10 compliance risk score and estimated remediation costs of ₹2–9 crore, primarily driven by undefined Extended Producer Responsibility (EPR) obligations under pharmaceutical waste regulations—a material 0.6% of annual revenue at the high end. The company's failure to disclose Scope 1 and 2 emissions despite manufacturing operations raises immediate SEBI BRSR Core Expansion non-compliance risk, potentially triggering enforcement action and delisting if reporting gaps persist in the next disclosure cycle. Water and GHG intensity risks (both 5.0/10) require urgent baseline establishment and mitigation roadmap; at India's carbon credit price of ₹600–900/tonne, unquantified emissions represent latent carbon liability. Priority actions: clarify EPR applicability and pharmaceutical waste disposal costs, establish emissions accounting framework, and ensure full BRSR P6 environmental disclosure compliance to mitigate regulatory and capital market penalties.

Source: Indoco Remedies Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.

← Back to ESG Quotient Dashboard Share on LinkedIn Browse all companies →